Pentixapharm Holding AG (ETR:PTP)

Germany · Delayed Price · Currency is EUR

1.982

-0.023 (-1.15%)

At close: Aug 1, 2025, 5:30 PM CET

Verve Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-16.86	-13.98	-7.64	-1.96	-2.49
Depreciation & Amortization	0.97	0.07	0.15	0.11	0.11
Asset Writedown & Restructuring Costs	19.01	19.01	-	-	-
Other Operating Activities	-3.86	-3.7	1.8	-0.22	0.85
Change in Accounts Receivable	-1.95	-7.64	0.41	0.01	-0
Change in Accounts Payable	-6.89	-0.21	2.34	-0.22	0.16
Change in Other Net Operating Assets	-	-0.28	5.08	0.07	0.01
Operating Cash Flow	-9.57	-6.73	2.13	-2.2	-1.37
Capital Expenditures	-0.61	-0.62	-4.94	-4.05	-2.73
Sale of Property, Plant & Equipment	-	-	0.13	-	-
Cash Acquisitions	8.71	8.71	-	-4.07	-
Investment in Securities	-	-	-0.53	-	-
Investing Cash Flow	8.1	8.08	-5.35	-8.12	-2.73
Issuance of Common Stock	19.89	19.89	25.66	-	5.29
Repurchase of Common Stock	-0.47	-0.47	-	-	-
Other Financing Activities	-0.62	3.52	-13.83	9.01	-0
Financing Cash Flow	18.8	22.94	11.83	9.01	5.29
Net Cash Flow	17.34	24.29	8.62	-1.3	1.19
Free Cash Flow	-10.17	-7.35	-2.81	-6.24	-4.1
Free Cash Flow Margin	-7424.09%	-524.24%	-43.18%	-157.24%	-157.75%
Free Cash Flow Per Share	-0.41	-0.30	-0.13	-	-
Cash Interest Paid	-	-	-	-	0
Cash Income Tax Paid	0.06	0.06	0.03	-	-
Levered Free Cash Flow	-8.49	-0.17	-6.87	-6.55	-
Unlevered Free Cash Flow	-8.46	-0.1	-6.76	-6.55	-
Change in Net Working Capital	2.14	-5.07	-1.84	1.26	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.